OptimizeRx Corporation

NasdaqCM:OPRX Rapporto sulle azioni

Cap. di mercato: US$81.4m

OptimizeRx Crescita futura

Future criteri di controllo 1/6

Si prevede che OptimizeRx aumenterà gli utili e i ricavi rispettivamente del 51.7% e 9% all'anno, mentre si prevede che l'EPS crescerà del 53.8% all'anno.

Informazioni chiave

51.7%

Tasso di crescita degli utili

53.8%

Tasso di crescita dell'EPS

Healthcare Services crescita degli utili30.6%
Tasso di crescita dei ricavi9.0%
Rendimento futuro del capitale proprion/a
Copertura analitica

Good

Ultimo aggiornamento20 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?

Nov 16
Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?

OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt

Jul 30
OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt

OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

Jan 09
OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)

Aug 24
Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)

OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely

Aug 16
OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely

Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?

May 31
Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?

OptimizeRx: A Top Candidate For My Speculative 'Bio Boom' Portfolio

Oct 12

Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?

Sep 23
Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?

OptimizeRx extends reach with Cooler Screens Partnership

Jul 26

OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability

Jun 27

The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business

Nov 16
The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business

Why We Think OptimizeRx Corporation's (NASDAQ:OPRX) CEO Compensation Is Not Excessive At All

Aug 13
Why We Think OptimizeRx Corporation's (NASDAQ:OPRX) CEO Compensation Is Not Excessive At All

A Look At The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)

Jul 15
A Look At The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)

Here's Why We're Not At All Concerned With OptimizeRx's (NASDAQ:OPRX) Cash Burn Situation

Jun 24
Here's Why We're Not At All Concerned With OptimizeRx's (NASDAQ:OPRX) Cash Burn Situation

Investors Will Want OptimizeRx's (NASDAQ:OPRX) Growth In ROCE To Persist

May 10
Investors Will Want OptimizeRx's (NASDAQ:OPRX) Growth In ROCE To Persist

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:OPRX - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/2026103-8N/AN/A1
12/31/2025100-11N/AN/A7
12/31/202489-18N/AN/A7
9/30/202488-24-1-2N/A
6/30/202483-18-2-2N/A
3/31/202478-18-6-5N/A
12/31/202372-18-8-7N/A
9/30/202363-1402N/A
6/30/202362-1424N/A
3/31/202362-1466N/A
12/31/202262-111011N/A
9/30/202263-1067N/A
6/30/202264-733N/A
3/31/202264-333N/A
12/31/202161001N/A
9/30/2021571-1-1N/A
6/30/2021521-1-1N/A
3/31/202147-1-1-1N/A
12/31/202043-2-6-6N/A
9/30/202034-6-6-5N/A
6/30/202029-7-7-6N/A
3/31/202027-5-8-6N/A
12/31/201925-3-3-2N/A
9/30/201924-101N/A
6/30/201924123N/A
3/31/201922022N/A
12/31/201821011N/A
9/30/201819000N/A
6/30/201816-1N/A-2N/A
3/31/201814-1N/A-2N/A
12/31/201712-2N/A-1N/A
9/30/201710-2N/A-2N/A
6/30/20179-2N/A-1N/A
3/31/20178-2N/A0N/A
12/31/20168-2N/A0N/A
9/30/20167-2N/A0N/A
6/30/20168-1N/A0N/A
3/31/20167-1N/A0N/A
12/31/20157-1N/A1N/A
9/30/201570N/A1N/A
6/30/201570N/A0N/A
3/31/201570N/A0N/A
12/31/20147-1N/A0N/A
9/30/20146-1N/A1N/A
6/30/20146-1N/A1N/A
3/31/20145-1N/A1N/A
12/31/201350N/A1N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che OPRX rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che OPRX rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che OPRX rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di OPRX ( 9% all'anno) crescerà più rapidamente del mercato US ( 9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di OPRX ( 9% all'anno) crescerà più lentamente di 20% all'anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di OPRX è previsto essere elevato tra 3 anni


Scoprire le aziende in crescita